Market Overview

GNT Pharma's Ropesalazine Effective in Treating Dog Dementia

Share:
  • New translational paradigm for Alzheimer's disease
  • World's first neuroprotection drug for dog dementia

GNT
Pharma
said Ropesalazine,
a drug candidate for Alzheimer's disease (AD), has shown an outstanding
beneficial efficacy in a pilot clinical trial conducted for dogs with
cognitive dysfunction syndrome (CDS) or dementia.

CDS is a progressive neurodegenerative disorder of senior dogs and
characterized by altered interaction with family, disorientation,
sleep/wake cycle changes, increased house soiling, and activity change.
There is no cure for the disease.

Ropesalazine
is a multi-target drug to prevent both inflammation and free radicals
that contribute to nerve cell death, amyloid plaque production, and
neurofibrillary tangle formation which are pathological hallmarks of AD.

Ropesalazine was found to attenuate nerve cell death and amyloid plaques
as well as inflammation and oxidative stress in transgenic AD mice
models. Ropesalazine reduced cognitive deficit in APP/PS1 AD mice at
early, moderate, and late stages. The safety of Ropesalazine was proven
in human as well as rats and dogs.

GNT Pharma scientists noticed that CDS is accompanied by nerve cell
death, amyloid plaques, and neurofibrillary tangles similar to AD, and
designed a pilot study to investigate if Ropesalazine would alleviate
signs of CDS.

The study was conducted on six companion dogs aged 10 or older that
revealed severe cognitive dysfunction scored according to canine
cognitive dysfunction rating scale and canine dementia scale. Within 8
weeks following daily oral administration of Ropesalazine, all six dogs
returned to the normal range of cognitive function and daily activity.

Dr. Jae Bong Moon, veterinarian and head of Irion Animal Hospital in
Seoul who led the study, was excited with the result, saying "The
companion dogs failed to recognize their owners before the treatment. It
was so amazing to see the dogs that wagged their tails for their owners
and cuddled up to them within 8 weeks of Ropesalazine treatment.
Ropesalazine appeared to cure CDS."

Encouraged with promising efficacy of Ropesalazine for CDS, GNT Pharma
will move toward the next clinical study for approval of Ropesalazine as
a drug for the treatment of CDS. The company assigned Professor
Byeong-Teck Kang, director of Chungbuk National University Veterinary
Medical Center, as a principal investigator. GNT Pharma plans to
complete the clinical trial and launch Ropesalazine for the treatment of
CDS in companion animals in 2019.

"We are impressed with such a huge beneficial effect of Ropesalazine for
CDS even within 8 weeks of treatment," GNT Pharma CEO & President Byoung
Joo Gwag said, "we will initiate a pivotal phase II study of
Ropesalazine for patients with AD next year, hoping to launch
Ropesalazine as the first disease-modifying AD therapy within next five
years."

View Comments and Join the Discussion!